Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469155 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Phase 3 study, sponsored by Intra-Cellular Therapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT02469155 is a Phase 3 study that has completed, run by Intra-Cellular Therapies. The registered enrollment target is 696 participants.
The verdict
NCT02469155, a Phase 3 study, has completed, sponsored by Intra-Cellular Therapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG ITI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469155
The ClinicalTrials.gov registry entry for NCT02469155 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02469155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469155 about?
NCT02469155 is a clinical study titled "A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment". The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
What is the current status of trial NCT02469155?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2015-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02469155?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), ITI-007 (DRUG).
Who is sponsoring clinical trial NCT02469155?
This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.